American Journal of Kidney Diseases
Volume 53, Issue 2 , Pages 192-196 , February 2009

Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination Therapy Better Than Monotherapy and Safe in Patients With CKD?

  • Jeffrey S. Berns, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Jeffrey S. Berns, MD, University of Pennsylvania School of Medicine, Renal-Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, 3400 Spruce St, 1 Founders Pavilion, Philadelphia, PA 19104

References 

  1. KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(suppl 1):S1–S290
  2. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet. 2005;366:2026–2033
  3. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease (A meta-analysis of patient-level data). Ann Intern Med. 2001;135:73–87
  4. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–1140
  5. Strippoli GF, Bonifati C, Craig M, et al. : Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;CD006257
  6. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006;1:256–262
  7. Wenzel U. Aldosterone and progression of renal disease. Curr Opin Nephrol Hypertens. 2008;17:44–50
  8. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am J Kidney Dis. 2008;51:199–211
  9. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial. Am J Kidney Dis. 2008;52:486–493
  10. Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: Meta-analysis and metaregression. Am J Kidney Dis. 2008;52:475–485
  11. Jennings DL, Kalus JS, Coleman CI, et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: A meta-analysis. Diabet Med. 2007;24:486–493
  12. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30–48
  13. MacKinnon M, Shurraw S, Akbari A, et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48:8–20
  14. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559
  15. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–553
  16. McMurray JJ. ACE inhibitors in cardiovascular disease—unbeatable?. N Engl J Med. 2008;358:1615–1616
  17. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906
  18. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet. 2003;362:767–771
  19. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675
  20. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet. 2003;361:117–124
  21. Kunz R, Wolbers M, Glass T, Mann JF. The COOPERATE trial: A letter of concern. Lancet. 2008;371:1575–1576
  22. Bidani A. Controversy about COOPERATE ABPM trial data. Am J Nephrol. 2006;26:629
  23. Cohen DL, Townsend RR: Is there added value to adding ARB to ACE inhibitors in the management of CKD? J Am Soc Nephrol (in press)
  24. Griffin KA, Bidani AK. Progression of renal disease: Renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol. 2006;1:1054–1065
  25. Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet. 2008;372:511–512

PII: S0272-6386(08)01693-4

doi: 10.1053/j.ajkd.2008.11.016

American Journal of Kidney Diseases
Volume 53, Issue 2 , Pages 192-196 , February 2009

Article Tools